However, to get to know the extent of this pathway being a potential target in ameliorating NAFLD of the general hepatic condition, additional measurements (such as serum levels of markers of liver damage AST, ALT, inflammatory and apoptosis markers in the liver) are needed. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.